Articles tagged with Inhibitory Effects
Researchers at UNIST have introduced non-solvating electrolytes to significantly improve the performance and lifespan of organic electrode-based batteries. The study achieved remarkable improvements in capacity retention and rate performance, with over 91% capacity retention after 1000 cycles.
Rumbaugh's lab aims to understand the effects of dispersing bacteria from a biofilm on their susceptibility to antibiotics and on the host. They will use enzymes as tools to break up biofilms, allowing researchers to better comprehend the relationship between bacterial dispersal and infection outcomes.
A recent study has uncovered 145 genes crucial for genome stability, shedding light on genetic factors influencing human health over a lifespan. The research highlights the potential of SIRT inhibitors as a therapeutic pathway for cohesinopathies and other genomic disorders.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Scientists found that short-chain fatty acids produced by gut bacteria suppress allergic reactions by modulating mast cell activation and epigenetic modifications. This study provides new insights into the relationship between diet and immune system regulation, with potential applications in allergy treatment.
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.
Researchers identify successful treatment of granulomas in the skin with mTOR inhibitor sirolimus, which showed partial complete remission of symptoms in 7 out of 10 patients. The study suggests targeting both immune and non-immune cells in granulomas may prevent recurrence.
Researchers identified gartisertib as a potent ATR inhibitor that enhances cell death in patient-derived glioblastoma cell lines. The study also showed synergy between gartisertib and TMZ+RT treatment, with higher sensitivity to gartisertib observed in MGMT promoter unmethylated cells.
A study by Fujita Health University researchers unveiled novel insights into the brain's processing of movement and sensation. The findings suggest that signals from motor cortices do not primarily modulate sensory responses in primary sensory cortices, but rather pathways from secondary somatosensory cortex (S2) and sensory thalamus (...
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Researchers found that Angelica gigas extract improves vascular function in high-fat diet rats, reversing endothelial dysfunction and increasing NO bioavailability. The extract regulates IRE1α sulfonation and RIDD signaling, promoting NO production via the SIRT1-eNOS axis.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
Researchers revisited melatonin's effects on cancer in mice, finding that nighttime administration inhibits chemically induced mammary tumor development. The study highlights the importance of timing in using this freely available compound for cancer prevention and treatment.
A study has deciphered a mechanism to sensitize cancer cells to TRAIL agonist therapy, which has been ineffective due to tumor resistance. ERK5 inhibition restores sensitivity to antitumor treatments.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers have discovered that a nanoemulsion made from copaiba oil has antiviral effects against zika virus, showing 80% viral RNA inhibition. The study's results pave the way for developing medications or specific vaccines against zika.
A study from the University of Ottawa found that sleep deprivation significantly impacts decision-making processes, reducing neural responses to winning and losing outcomes. This can lead to diminished positive emotions in response to winning and negative emotions when faced with losses.
Researchers have elucidated the molecular mechanism of formaldehyde poisoning in a class of efficient hydrogen-producing biocatalysts. The study suggests that modifying the enzyme to resist formaldehyde inhibition could enable its use in bio-based industrial processes and understanding metabolic pathways.
A new AI tool combines cancerous and non-cancerous cell patterns to predict breast cancer outcomes, allowing for more precise treatment plans. This could lead to reduced chemotherapy duration and intensity for some patients.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
Researchers found that treating C. elegans with mitochondrial inhibitors extended their lifespan, improved pharyngeal muscle contraction, reduced lipofuscin content, and decreased energy consumption. The study suggests that these drugs could abrogate aging and extend human lifespan, offering a potential therapeutic approach.
Researchers found that stopping TNF inhibitors led to more flares and lower remission rates among RA patients who were already in sustained remission. This contrasts with those who continued treatment, highlighting the importance of personalized treatment approaches for RA patients.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
Researchers identified a mechanism that fuels cancer cell growth and developed a new strategy to restrict this process. By restricting glucose in lung cancer cells, they found it caused the cells to lose their specialized features, making them more aggressive.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
A new study reveals that mosquito eggs can tolerate extended desiccation by changing their metabolic pathway. By rewiring their polyamine and lipid metabolism, the eggs become more resistant to dehydration. This finding provides potential new ways to control the spread of Zika virus.
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
Researchers developed a promising strategy to reduce adverse reactions to nanoparticles by using complement inhibitors. The study showed that regulators being studied effectively inhibited complement activation by nanoparticles in human serum in vitro and animal models.
A Cornell-led collaboration created a 3D in-vitro model of human lymphatic vessels that revealed a surprising mechanism jamming up drainage: the protein ROCK2. Inhibiting ROCK2 reverses lymphedema effects, offering potential treatment for this condition.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Researchers have developed a new approach to treating herpes by inhibiting an enzyme that releases newly formed virus particles from infected cells. The inhibitors, made of oligosaccharides, significantly reduce the spread of the virus and may also impede cancer metastasis.
A groundbreaking study using functional neuroimaging has uncovered unique neural pathways linked to behavioral inhibitory control (BIC) processes. The study found that the prefrontal cortex plays a pivotal role in BIC, with the right inferior frontal cortex showing heightened activations.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
A groundbreaking review paper reveals the importance of GABA tone, the amount of GABA that regulates continuous signaling in the brain. The study identifies key mechanisms and functions, including astrocytes' role in regulating GABA tone and its impact on cognitive processes.
Scientists at CU Anschutz Medical Campus discover that long-term potentiation requires structural functions of CaMKII, not enzymatic actions. This breakthrough opens the door to therapeutic use of inhibitors targeting only CaMKII activity.
Researchers discovered that inhibiting IGF2BP1 can extinguish its cancer-causing effects, leading to the formation of neuroblastomas. The study provides a promising new potential therapeutic approach for treating this childhood cancer.
A team of KAUST researchers has found a critical protein that regulates cell division and proliferation in breast cancer and leukemia. Their work clears the way for the development of targeted drugs by refuting recent challenges to their approach.
The Texas Heart Institute has been awarded $1.14 million by the NIH to develop a novel, first-in-class drug for treating atherosclerotic cardiovascular disease. The goal of this research is to target lingering inflammation in patients with cardiovascular disease.
Researchers have discovered that estrogen promotes tumor growth in ERα-negative cancers, such as triple-negative breast cancer. Anti-estrogenic therapies, when combined with immune checkpoint inhibitors, drastically suppress tumor progression in mice models.
Researchers have found a promising new mechanism to target aggressive forms of prostate cancer, where the LSD1 protein is involved. By inhibiting LSD1, the tumor suppressor gene p53 can be reactivated, leading to suppression of tumor growth.
A new study demonstrates that a pill inhibiting a gut enzyme can protect mice from IBD symptoms and preserve intestinal barrier function. The experimental GCPII-inhibiting drug was shown to improve stool consistency, reduce rectal bleeding and inflammation, with no apparent side effects.
Researchers found that inhibiting NLRP3 signaling reduces podocyte senescence, improves lifespan, and slows down healthy podocyte aging in mice. This discovery holds promise for treating age-related kidney diseases.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers from Sahmyook University found that phyllodulcin, a natural sweetener found in hydrangeas, can efficiently inhibit amyloid beta (Aβ) aggregation and dissociate its aggregates in an animal model study. The study suggests that phyllodulcin may be useful in delaying the onset and progression of Alzheimer's disease.
Researchers discovered that nickel-cobalt alloy nanocrystals inhibit the activation of three inflammasomes, including NLRP3, NLRC4, and AIM2, in primary macrophages. The study found that these nanocrystals effectively treated colitis and acute peritonitis by reducing disease symptoms.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers at IRB Barcelona have developed new p38 inhibitors that selectively impair one of the activation pathways of the protein, allowing it to perform many of its normal functions. The inhibitors show therapeutic potential for heart diseases such as cardiac cell death and cardiotoxicity.
Researchers at Texas A&M University found that substance use impairs cognitive flexibility by inhibiting specific neurons. Chronic cocaine or alcohol use alters the local inhibitory brain circuit, leading to decreased cognitive flexibility and increased risk of academic deficits and lower quality of life.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
Researchers at Helmholtz Munich discovered that DHODH inhibitors sensitize cancer cells to ferroptosis by inhibiting ferroptosis suppressor protein-1 (FSP1), not DHODH itself. This finding confirms the crucial role of FSP1 in ferroptosis surveillance and opens up new avenues for developing effective cancer therapies.
Researchers have discovered that inhibitory neurons can transmit information over long distances in the prefrontal cortex, allowing for adaptive changes in behavior. This synchronization of gamma oscillations is associated with the realization of new rules and enables cognitive flexibility.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
CNRS scientists have identified a molecule that prevents parasites of Plasmodium from invading blood cells, paving the way for a new class of antimalarials. The discovery is based on the key role of myosin A in malaria infection and its inhibition by KNX-002.
Research suggests that aromatase inhibitors can limit the effectiveness of weight loss medications in breast cancer survivors. Studies have shown that these medications are less effective in women taking aromatase inhibitors, leading to reduced weight loss and increased risk of health complications.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.